GSK RSV shot approved by FDA, starting next blockbuster vaccine race
GSK secured the first-ever FDA approval for an RSV vaccine on Wednesday, ending half a century of failed efforts against the elusive, shape-shifting virus and officially starting what analysts expect will be a highly competitive and lucrative new vaccine market.
The FDA cleared GSK’s shot, which will be sold as Arexvy, for adults 60 and older. In a trial, it showed strong efficacy in stopping lower-respiratory tract infections as well as more severe disease. It’s given as a single dose.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.